Journal of Clinical and Experimental Ophthalmology
Open Access

Abstract

Intravitreal Ranibizumab for Macular Edema Secondary to Juxtafoveal Retinal Telangiectasia Type 1A

Ruwan A. Silva and Ninel Z. Gregori

Purpose: To describe the clinical, angiographic, and optical coherence tomography (OCT) findings of a patient with cystoid macular edema (CME) in juxtafoveal retinal telangiectasis (JXT) treated with intravitreal ranibizumab injections.
Methods: In the setting of a tertiary referral center, a patient with a long history of Leber’s miliary aneurysms was later diagnosed with ipsilateral juxtafoveal retinal telangiectasis (JXT) type 1A with associated CME. The patient was treated with eight intravitreal injections of 0.5 mg of ranibizumab and followed with examination and Spectral-Domain Optical Coherence Tomography (OCT) for 14 months.
Results: At baseline, fluorescein angiography demonstrated macular telangiecatasis and aneurysms with late leakage. The OCT showed a large area of intraretinal fluid in the area of telangiectasis. CME resolved after the first intravitreal ranibizumab injection and the vision gradually improved from 20/50 to 20/20−1 over 5 months. Repeat ranibizumab injections were required to keep the macula dry over 14 months. No adverse events were noted.
Conclusions: Intravitreal ranibizumab injections resulted in restoration of macular architecture and vision improvement in a patient with JXT type 1A. Ranibizumab should be considered as a treatment option in this condition.